Chongqing Precision Biotechnology's Dual-Target CAR-T Therapy C-4-29 Receives IND Approval for Relapsed/Refractory Multiple Myeloma

Recently, the CDE official website showed that Chongqing Precision Biotech Co., Ltd. (hereinafter referred to as “Chongqing Precision”)’s CAR-T cell product C-4-29 cell preparation’sClinical TrialsThe application has received implicit approval from the Center for Drug Evaluation of the National Medical Products Administration for the treatment of patients aged ≥18 years with relapsed/refractory multiple myeloma. To date, Chongqing Precision Biotech Co., Ltd. has obtained IND approvals for four CAR-T projects.

Public information shows that Chongqing Precision Biotech Co., Ltd. was established in 2016, focusing onTumor、AutoimmunitySexually transmitted diseases,Metabolic Diseasesand degenerative diseases, leveraging precise biological therapies (CAR-T, TCR-T, CAR-NK) as a starting point to conduct research, development, and translation in precision medicine, precision healthcare, and biopharmaceuticals.

Currently, Chongqing Precision Biotech Co., Ltd. possesses key technologies for tumor antigen screening and humanized monoclonal antibodies.TumorMicroenvironment-specific CAR technology, universal CAR technology, bispecific CAR, and key technologies for reversing immune suppression, etc., to establish a biopharmaceutical R&D and translation platform, includingBiobank, bioinformatics analysis platform, genetic testing platform, gene editing and screening platform, cell preparation platform, pilot-scale platform for biologics, testing platform, and other R&D platforms, totaling 20,000 square meters.

The C-4-29 cell preparation approved for IND in this instance is a CAR-T product independently developed by Chongqing Precision Biotech Co., Ltd. for the treatment of multiple myeloma (MM), exploratoryClinical TrialDemonstrated favorable safety and efficacy, with the potential to further reduce clinicalTumorthe risk of recurrence.

In addition, Chinese cell therapy companies such as Hengrundaisheng, Gracell Biotechnologies, and Hebei Senlang have also successively laid out their pipelines for dual-target CAR-T products.Bio ValleyBioon.com）

Editor's PicksMeeting2021 (12th) International Online Symposium on Cell Therapy

http://meeting.bioon.com/2021cell-therapies